Vemurafenib and cobimetinib combined BRAF-MEK inhibitors  

     

Select             pdf
Trial Studied trt Control trt patientstagsROB Trial resultdeath (overall survival) progression or death (progression free survival PFS)

melanoma  

Larkin, 2014      NCTvemurafenib and cobimetinibvemurafenibsuggesting-49%